SCHEMBL1470751

SCHEMBL1470751

CC(C)(C)OC(=O)N(CCNc1ccccc1[N+](=O)[O-])Cc1cccc(C(=O)N2CCCCC2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.42
MAPK1 P28482 1/20 0.42
ALDH1A1 P00352 8/20 0.42
GAA P10253 2/20 0.42
HTT P42858 4/20 0.41
LMNA P02545 3/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
RECQL P46063 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GPR174 Q9BXC1 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
AR P10275 1/20 0.39
HDAC1 Q13547 1/20 0.39
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5695823 0.88 GPR174 (0.44) SMN1; SMN2MAPK1ALDH1A1GAAHTT
SCHEMBL1470736 0.87 NPC1 (0.41) SMN1; SMN2ALDH1A1HTTLMNAMAPT
SCHEMBL1470893 0.87 SMN1; SMN2 (0.40) SMN1; SMN2MAPK1ALDH1A1GAAHTT
SCHEMBL1470908 0.86 HTR1A (0.42) SMN1; SMN2ALDH1A1GAAHTTLMNA
SCHEMBL1471446 0.85 HDAC1 (0.41) SMN1; SMN2ALDH1A1HTTLMNARECQL
SCHEMBL1471442 0.84 HTR1A (0.52) GAAHTTMEN1KMT2AHTR1A
SCHEMBL1470808 0.83 HDAC3 (0.47) SMN1; SMN2ALDH1A1GAALMNAMAPT
SCHEMBL8306315 0.78 KMT2A (0.51) SMN1; SMN2ALDH1A1GAAHTTLMNA
SCHEMBL1471423 0.78 ALDH1A1 (0.47) SMN1; SMN2MAPK1ALDH1A1GAAHTT
SCHEMBL1471024 0.76 HTR1A (0.53) GAAHTTMEN1KMT2AHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915420-B2 Aryl piperidine amides JANSSEN PHARMACEUTICA NV (BE) 2011-03-29 US disclosed
US-20080009521-A1 Aryl Piperidine Amides HUANG CHARLES Q 2008-01-10 US disclosed
US-7276610-B2 Aryl piperidine amides JANSSEN PHARACEUTICA, NV (BE) 2007-10-02 US disclosed
EP-1660472-A1 ARYL PIPERIDINE AMIDES JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-31 EP disclosed
WO-2005021525-A1 ARYL PIPERIDINE AMIDES JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-10 WO disclosed
US-20050049239-A1 Aryl piperidine amides JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009521-A1 Aryl Piperidine Amides BDNF, NTRK2, OPRL1 SMN1; SMN2 519/4885MAPK1 1699/4885ALDH1A1 952/4885
US-20050049239-A1 Aryl piperidine amides BDNF, NTRK2, OPRL1 SMN1; SMN2 519/4885MAPK1 1699/4885ALDH1A1 952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.